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The idea of bone tissue regeneration calls for the development of new biomaterials. We
designed a novel ceramic-polymer composite material that expresses the feature of drug
carrier to restore facial and cranial bone defects. The ceramic phase consists of BCP with
different proportions of HAp/â-TCP, while the polymer phase is poly(D, L-lactide) which is a
carrier for clindamycin. The purpose of this study was to determine whether the eluates of the
designed biomaterial have the potential to cause inflammatory response or express
cytotoxicity in vitro. The elution was carried out for 24 hours or 6 days. Cells were incubated
for 24 or 48 h with eluates of six types of materials: HP1 group (HAp with polylactide in
composition 61%-39%); HP2 group (HAp with polylactide in composition 80%-20%); HPC
group (HAp with polylactide and clindamycin); BP group (BCP with polylactide); BPC
group (BCP with polylactide and clindamycin); B group (BCP). Cytotoxicity was determined
with a commercial cytotoxicity kit on human fibroblasts from the hs-27 cell line. ELISA was
used to measure cytokine expression for pro-inflammatory IL-6 and IL-8. Eluates of the
novel ceramic-polymer composite material with the feature of a drug carrier (BCP and
polylactide with clindamycin) did not produce a cytotoxic effect in the human fibroblast
hs-27 cell line, nor did any of the tested biomaterials. The tested materials did not influence
the production of pro-inflammatory cytokines. Therefore the novel ceramic-polylactide
composite material may be further tested in vivo as a promising alternative for known
biomaterials in bone defect reconstruction.
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The idea of regenerative dentistry calls for
the development of new biomaterials and bio-
logical methods of treatment. This biological ap-
proach would allow for the regeneration of eve-
ry tissue of the maxillofacial region that
was injured or lost due to disease or trauma.
A model bone-replacing material should fulfill
defined criteria: it should be non-toxic, noncaus-
tic and biocompatible. This material should ex-
press bioactivity, biocompatibility and osteocon-
ductivity. Once implanted in vivo it should be
overgrown with newly synthesized autologous
bone and has to be completely replaced by this tis-
sue with time.
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Two of the most commonly used bone-
replacement materials: hydroxyapatite (HAp) and
â-tricalciumphosphate (â-TCP) are very similar to
themineral phase of human teeth and bone. HAp is
highly biocompatible, expresses osteoconductiv-
ity, is bioactive and has the potential to form
chemical bonds with human bone tissue. â-TCP is
bioactive, as well as biocompatible and resorbable
(ŒLÓSARCZYK 2003; KOEPP et al. 2004; SOPYAN
et al. 2007). However, both of these materials ex-
press some undesirable features. HAp is not de-
graded in vivo, and therefore is not fully replaced
by bone tissue, being only a type of construct that
supports bone synthesis on its surface, while
â-TCP expresses uncontrolled process of resorp-
tion, which implies differences between the
amounts of newly synthetized bone tissue and im-
plant material (NERY et al. 1992). Biphasic Cal-
cium Phosphate Ceramic (BCP) is a mixture of
HAp and â-TCP that possesses the advantageous
features of both of these materials. However, al-
though it is chemically stable in a biological envi-
ronment, it has a high value of YoungModule and
therefore can crack once implanted in vivo
(LEGEROS et al. 2003).
Not only bioceramic materials are used as bone-
replacing implants. Natural or synthetic polymers,
such as polylactic acids (PLLAor PDLLA) are hy-
drolyzed in vivo to lactic acid which is a natural
component of the human body. They are biocom-
patible, express good mechanical resistance and
can be easily shaped into polylactide implants
of different sizes and forms (LI CHUN et al. 2008).
PLLA and PDLLA can also be used as drug carri-
ers, which is subject to experimentation in the field
of biomaterial research. The use of drug carries
decreases drug toxicity, as the therapeutic sub-
stance is implanted directly into the place of dis-
ease and only there does it express its biological
action (COSIJNS et al. 2007; FERRAZ et al. 2007;
HONG et al. 2011; KANELLAKOPOULOU and
GIAMARELLOS-BOURBOULIS 2000; MANGANO
et al. 2003). However, the chemical resistance in
the in vivo environment of polymers is decreased
when compared with ceramic materials, BCP on
the other hand is not elastic and therefore suscepti-
ble to cracking. In this study we used hydroxyapa-
tite with polylactide in two different concentrations
as one of the tested materials.
In order to eliminate the disadvantages and in-
crease the number of beneficial features in onema-
terial that can be used to restore facial and cranial
bone defects, a novel ceramic-polymer composite
material has been obtained from BCP and poly-
mers, which has the feature of a drug carrier. Its ce-
ramic phase consists of BCP with different
proportions of HAp/â-TCP, while the polymer
phase is poly(D, L-lactide) that is a carrier for clin-
damycin. The structure of thematerial is organized
into porous granules of 250 ìm to 1000 ìm size
which should enable a better placement inside
bone defect and decrease the risk of material
movement after implantation, diminishing the risk
of post-operative complications. The porous struc-
ture creates an ideal niche for the newly synthe-
sized bone to grow which should result in higher
bond strength between the material and bone tis-
sue. The polylactide layer improves not only the
elasticity of the material, but also the adhesion of
cells to the surface of the implanted material. The
possibility of drug deposition inside the material
makes it possible to treat the inflammatory re-
sponse after surgical procedure and eliminate
post-operative complications.
Taking into consideration all advantages and
disadvantages of the mentioned types of bone-
replacing materials, we created four different ex-
perimental groups of known materials in different
combinations of compounds: HApwith polylactide
in composition 61%-39%; HAp with polylactide
in composition 80%-20%; HAp with polylactide
and clindamycin; BCP, and compared them with
the novel ceramic-polylactide composite material
with a feature of drug carrier – BCP + polylactide
with or without clindamycin invented by our re-
search group.
One of the steps in the evaluation of usefulness
of anymedical product or material is to check their
possible cytotoxic effect on human cells. This can
be tested either by directly using thematerial in tis-
sue cultures or by preparing eluates of the materi-
als in different solvents followed by the evaluation
of the eluate cytotoxicity in cell culture conditions
(ISO 10993 standard “Biological evaluation of the
medical devices”).
The purpose of this study was to determine
whether the ceramic-polylactide composite material
with a feature of drug carrier – BCP + polylactide
with or without clindamycin (eluates used in ex-
perimental groups 4 and 5) – has the potential to
cause inflammatory response or expresses cyto-
toxicity in vitro and to compare it with alternative
graft materials: hydroxyapatite with polylactide in
two different concentrations (group 1 and 2), as
well as hydroxyapatite with polylactide and clin-
damycin (group 3) and single BCP (group 6).
Materials and Methods
Abbreviations
BCP – biphasic Calcium Phosphate Ceramic
HAp – hydroxyapatite
PDLLA – poly(D, L-lactide)
PLLA – poly(L-lactic acid)
â-TCP – â-tricalcium phosphate
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Preparation of the eluates from the implant mate-
rials
To test the influence of the implant materials in
in vitro conditions, eluates of the prepared materi-
als were divided into 6 experimental groups after
dissolving in polar and non-polar solvents. The
6 experimental groups were: group 1 – HP1 (HAp
with polylactide in composition 61%-39%); group
2 – HP2 (HAp with polylactide in composition
80%-20%); group 3 – HPC (HAp with polylactide
and clindamycin); group 4 – BP (BCP with poly-
lactide); group 5 – BPC (BCPwith polylactide and
clindamycin); group 6 – B (BCP). All materials
from the 6 groups were prepared in the laboratory.
Pure DMEM medium was chosen as a polar sol-
vent and DMSO as a polar aprotic solvent for non-
polar compounds. 20 mg of each implant material
was used for elution in 100 ìl of each solvent ac-
cording to recommendations of the ISO regula-
tion; elutionwas carried out in 37oC for 24 hours or
6 days for a prolonged time of material release.
The eluates were prepared according to the ISO
10993 standard “Biological evaluation of the
medical devices” (ISO 10993 standards). We used
only one selected amount of eluates to treat cells,
because DMSO concentration in the medium was
already about 1% and there was no possibility to
use multiple samples, they could be used in the
case of dissolution in DMEM only. Because the
highest obtained concentrations did not show cy-
totoxic activity, dilutions were not prepared.
Cell culture conditions for the evaluation of
possible cytotoxicity of the eluates from implant
materials
Human fibroblasts from the hs-27 cell line were
cultured in the cell culture medium DMEM (Hy-
Clone) supplementedwith 10% fetal bovine serum
(FBS, HyClone), penicillin (1000 U/ml) (Gibco)
and streptomycin (1000 U/ml) (Gibco) – a com-
plete cell culture medium. We decided human fi-
broblasts will be good model cells for cytoxicity
evaluation in this study, as they are widely propa-
gated in human body, especially in connective tis-
sue, are relatively easy in laboratory procedures
such as culture, cell passages and others. To test
the cytotoxicity of the eluates from implantmateri-
als in cell culture conditions, fibroblasts were
seeded on a 96-well tissue culture plate (BD Fal-
con) in the amount of 8x103 cells per well for
24 hours before the experiment. On the day of the
experiment, the culturemediumwas replacedwith
a fresh one and the eluates were added in the
amount of 2 ìl per 200 ìl of the medium in the
well. Cells were incubated with the eluates or as
controls for the next 24 or 48 hours as indicated
and then cell culture supernatantswere collected to
measure the possible cytotoxicity effect on the
cells.
Cytotoxicity was determined using the Cytotox-
icity Detection KitPLUS (LDH) (Roche) accord-
ing to manufacturer’s instruction. As a negative
control, appropriate amounts of either pure
DMEM or DMSO were added at the beginning of
the experiment and for the positive control of the
cytotoxic effect cells were additionally treated
with 0.1% Triton X-100 (Sigma) or appropriate
buffer from the Cytotoxicity Detection KitPLUS
(LDH) (Roche) for 2 hours before collecting cell
culture supernatants to ensure their complete lysis.
The product of the reaction from the Cytotoxicity
Detection KitPLUS (LDH) was measured using
a spectrophotometer microplate reader (Epoch,
BioTek) with the software Gen5 2.0. Experiments
were performed four times in triplicates on each
plate, which were averaged before entering the
analysis.
Measurement of cytokine production by eluates
from implant materials
To detect the production of cytokines in cell cul-
tures upon treatment with the material eluates,
cells were seeded a day before the experiment on
24-well plates in the amount of 60x103 cells per
well and cultured in 0.8 ml of complete medium in
the same cell culture conditions as described
above. On the day of the experiment the medium
was replaced with 0.8 ml of fresh one in each well
and the appropriate eluates were added in the
amount of 1 ìl per each 100ìl ofmedium in awell.
Additionally, the LPS was used as a positive con-
trol of cytokine production in a concentration of
400 ng/ml and pure DMEM or DMSOwere added
in amounts similar to eluates as negative controls.
Cells were incubated with appropriate factors for
24 hours and then cell culture supernatants were
collected formeasurement of cytokine production.
The measurement of cytokine expression was per-
formed usingQuantikine ELISA 1 kits (R&DSys-
tems) for pro-inflammatory IL-6 and IL-8
according to the manufacturer’s instructions. The
experiments were performed three times inde-
pendently in triplicates, which were averaged be-
fore entering the analysis.
Data presentation
All data are presented in graphs as themean ±SD.
We decided that 4 and 3 independent measure-
ments per group are enough to reach the desired
precision, as it is generally accepted to present re-
sults being the average of at least three independ-
ent experiments. To achieve measurement inde-
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pendence, each experiment started with a new cell
bank with a comparable number of passages.
Statistical analysis was not carried out because
of the number of results (9 to 12 for cytotoxicity
determination and 6 to 9 for the production of cyto-
kines) and sometimes large standard deviations.
Since the difference between the positive control
and the tested samples was undisputed, statistical
analysis would not bring any additional informa-
tion.
Results and Discussion
The results indicate that none of the evaluated
eluates from any experimental group induced a cy-
totoxic effect in the human fibroblast hs-27 cell
line. Material eluates with either DMEM or
DMSO did not cause a decrease in cell viability as
measured with the test (Fig. 1a, b). A prolonged
elution time also did not influence the cytotoxicity
of the eluates (Fig. 1c, d). In the case of the nega-
tive control (pure DMEM or DMSO) and positive
control (0.1% Triton), the registered cytotoxicity
was 0% and 100%, respectively.
These results were additionally confirmed by
microscopic analysis of cell cultures inwhich none
of the cells of the experimental groups differed
from the negative control group and all showed
signs of healthy morphology and growth (data not
shown). In conclusion, the novel ceramic-polymer
material fulfills the criteria of a biomaterial in the
aspect of being non-cytotoxic.
Since implant materials can interact with living
tissues of the organism, another question was
asked: if they can induce an inflammatory re-
sponse by initiation of the production of inflamma-
tory cytokines. There are many tests available to
check material cytotoxicity in laboratory condi-
tions such as:MTT assay, agar diffusion test, filter
diffusion test and many more. In this study we
investigatedwhether the eluates of the implantma-
terials can impact the production of pro-
inflammatory cytokines using IL-6 and IL-8 Cyto-
toxicity Detection KitPLUS (LDH) (Roche). The
results indicate that the eluates tested here do not
Fig. 1. Cytotoxicity of the implant materials (group 1 to 6) dissolved for 24 h or 6 days in DMEM (a) (c) or DMSO (b) (d).
Positive control – 0.1% Triton X-100 (Sigma) or appropriate buffer from the Cytotoxicity Detection KitPLUS (LDH) yielded
100% cytotoxicity (result not shown in the graph to avoid its overloading). Negative control – DMEM or DMSO solutions.
HP1 – HAp with polylactide in composition 61%-39%; HP2 – HAp with polylactide in composition 80%-20%; HPC – HAp
with polylactide and clindamycin; BP – BCP with polylactide; BPC – BCP with polylactide and clindamycin; B – BCP. Bars
represent mean ±SD of 4 independent experiments.
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induce the production of neither IL-6 nor IL-8 –
strong pro-inflammatory cytokines (Fig. 2a-d).
However, it should be noted that these data indi-
cate only the fact that the eluates of implant mate-
rials do not influence the production of pro-
inflammatory cytokines IL-6 and IL-8, and we can
only suspect that the implantedmaterial should be-
have similarly. These results should be further
confirmed in in vivo studies, where novel
ceramic-polymer material will be implanted into
tissue at a macroscopic scale.
One of themost interesting and rapidly develop-
ing areas for biomaterials applications is the con-
trolled and targeted delivery of drugs.Wemanaged
to modify novel ceramic-polymer material to be
a drug carrier for one of the most widely applied
antibiotics in dentistry – clindamycin.We proved that
the addition of clindamycin (group 5) does not cause
any changes in cytotoxicity or potential to cause
inflammatory response in comparison to ceramic-
polymer material without the drug (group 4). The
concentration of clindamycin and the possible
amounts of clindamycin released to the eluates are
not described in the current study, as we aimed at
only determining if clindamycin presence in the
biomaterial will have any influence on inflamma-
tion in cell culture. In case of the induction of an in-
flammatory response or any other adverse effects
on the cells, no further experiments would be car-
ried out. The concentration of clindamycin needed
for release of a particular amount will be the sub-
ject of our next experiment.
The obtained results are similar to those in other
studies on biocompatibility of this type of bioma-
terial. LEI et al. (2012) studied properties of bipha-
sic calcium phosphate scaffolds coated with
HAp/PLLA composites for bone tissue engineer-
ing applications. In vitro cytotoxicity was investi-
gated with the MTT assay on the rat osteoblastic
ROS17/2.8 cell line. The results showed good bio-
compatibility, showing no negative effect on cell
growth and proliferation. We therefore decided to
use the human fibroblast cell line in our study, as
more relevant according to possible future appli-
cations, as well as the Cytotoxicity Detection Kit-
Fig. 2. IL-6 (a, b) and IL-8 (c, d) production by human fibroblasts hs-27 treated with the implant material eluates (group 1 to 6)
dissolved for 24 h or 6 days in DMEM or DMSO. LPS (400 ng/ml) was used as a positive control of cytokine production and
pure DMEM or DMSO solutions in amounts similar to eluates as negative control. HP1 – HAp with polylactide in
composition 61%-39%; HP2 – HAp with polylactide in composition 80%-20%; HPC – HAp with polylactide and
clindamycin; BP – BCP with polylactide; BPC – BCP with polylactide and clindamycin; B – BCP. Bars represent mean ±SD
of 3 independent experiments; * – not detected.
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PLUS (LDH), to confirm lack of cytotoxicity with
a different method.
Eluates of a novel ceramic-polylactide compos-
ite implant material synthesized by us (BCP and
polylactide with clindamycin) do not cause cyto-
toxicity in human fibroblasts, nor the production
of pro-inflammatory cytokines in vitro. Future
tests should include its biocompatibility in respect
to chemical composition, to avoid adverse tissue
reactions after implantation, as well as its resis-
tance to biological degradation, strength to sustain
loading and ability to minimize bone resorption.
Further in vivo studies should determine if it is
a potentially good alternative for known biomate-
rials in bone defects reconstruction and could be
a useful tool to replace or augment the function of
human bone tissue in the future.
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